Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 13/20 | 0.59 |
| ▸ | ATG7 | O95352 | 1/20 | 0.46 |
| ▸ | STAT6 | P42226 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1795761 | 0.81 | SLC29A1 (0.76) | SLC29A1ATG7STAT6TP53CYP3A4 | |
| SCHEMBL5273825 | 0.77 | SLC29A1 (0.77) | SLC29A1STAT6TP53CYP3A4HIF1A | |
| SCHEMBL18630522 | 0.75 | ADORA3 (0.56) | SLC29A1TP53 | |
| SCHEMBL24505818 | 0.73 | SLC29A1 (0.76) | SLC29A1STAT6TP53CYP3A4HIF1A | |
| SCHEMBL18630414 | 0.72 | NNMT (0.40) | — | |
| SCHEMBL20434965 | 0.72 | SLC29A1 (0.74) | SLC29A1STAT6TP53CYP3A4HIF1A | |
| SCHEMBL20434964 | 0.72 | SLC29A1 (0.74) | SLC29A1STAT6TP53CYP3A4HIF1A | |
| SCHEMBL20435031 | 0.71 | SLC29A1 (0.72) | SLC29A1STAT6TP53CYP3A4HIF1A | |
| SCHEMBL20008053 | 0.71 | ADORA2A (0.45) | TP53CYP3A4HIF1A | |
| SCHEMBL20434985 | 0.70 | SLC29A1 (0.70) | SLC29A1STAT6TP53CYP3A4HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENIUM PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | SLC29A1 1761/4885ATG7 2417/4885STAT6 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.